ReviewCurrent diabetes reports2016
The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases.
Review in Current diabetes reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- miR-Novel-80 Suppresses Porcine Reproductive and Respiratory Syndrome Virus Replication by Targeting the ViralAnimals : an open access journal from MDPI · 2026Article
- Psychosocial stress-associated alterations in microRNAs and their relevance for metabolic diseases: A systematic review.Comprehensive psychoneuroendocrinology · 2026Review
- Epigenetic regulation in type II diabetes: linking molecular mechanisms to clinical management.Journal of diabetes and metabolic disorders · 2026Review
- The Significance of miRNA-375 in β-cell Function and Autoimmune Destruction in Type 1 Diabetes Mellitus: A Review Article.Reviews on recent clinical trials · 2026Article
- Small interfering RNA (siRNA) as a potential gene silencing strategy for diabetes and associated complications: challenges and future perspectives.Journal of diabetes and metabolic disorders · 2024Review
- Non-Genetic-Induced Zebrafish Model for Type 2 Diabetes with Emphasis on Tools in Model Validation.International journal of molecular sciences · 2023Review
- miRNA Delivery by Nanosystems: State of the Art and Perspectives.Pharmaceutics · 2021Review
- Circulating miR-330-3p in Late Pregnancy is Associated with Pregnancy Outcomes Among Lean Women with GDM.Scientific reports · 2020Article
- The clinical potential of circulating microRNAs in obesity.Nature reviews. Endocrinology · 2019Review
- LncRNA NEAT1 promotes extracellular matrix accumulation and epithelial-to-mesenchymal transition by targeting miR-27b-3p and ZEB1 in diabetic nephropathy.Journal of cellular physiology · 2019Article
- Ocular-Component-Specific miRNA Expression in a Murine Model of Lens-Induced Myopia.International journal of molecular sciences · 2019Article
- Oral Delivery of miRNA With Lipidic Aminoglycoside Derivatives in the Breastfed Rat.Frontiers in physiology · 2019Article
- A novel peptide RIFV suppresses human adipocyte differentiation through the inhibition of C/EBP-β expression.Nutrition & metabolism · 2019Article
- Circulating miRNAs Associated with Arsenic Exposure.Environmental science & technology · 2018Article
- MicroRNAs as Regulators of Insulin Signaling: Research Updates and Potential Therapeutic Perspectives in Type 2 Diabetes.International journal of molecular sciences · 2018Review
- MicroRNA profiling of diabetic atherosclerosis in a rat model.European journal of medical research · 2018Article
- Silencing Lin28 promotes apoptosis in colorectal cancer cells by upregulating let‑7c targeting of antiapoptotic BCL2L1.Molecular medicine reports · 2018Article
- Exosomes as Mediators of the Systemic Adaptations to Endurance Exercise.Cold Spring Harbor perspectives in medicine · 2018Review
- The Destiny of Glucose from a MicroRNA Perspective.Frontiers in endocrinology · 2018Review
- The Emerging Role of microRNAs in Aquaporin Regulation.Frontiers in chemistry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
MicroRNAs (miRNAs) are small, non-coding, RNA molecules that regulate gene expression. They have a long evolutionary history and are found in plants, viruses, and animals. Although initially discovered in 1993 in Caenorhabditis elegans, they were not appreciated as widespread and abundant gene regulators until the early 2000s. Studies in the last decade have found that miRNAs confer phenotypic robustness in the face of environmental perturbation, may serve as diagnostic and prognostic indicators of disease, underlie the pathobiology of a wide array of complex disorders, and represent compelling therapeutic targets. Pre-clinical studies in animal models have demonstrated that pharmacologic manipulation of miRNAs, mostly in the liver, can modulate metabolic phenotypes and even reverse the course of insulin resistance and diabetes. There is cautious optimism in the field about miRNA-based therapies for diabetes, several of which are already in various stages of clinical trials. This review will highlight both the promise and the most pressing challenges of therapeutic miRNA silencing in diabetes and related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.